We verified Y4's in vivo effects in LX22—a highly aggressive patient-derived xenograft model of small cell lung cancer23—and found similar results on tumour growth inhibition, reduction of proliferative index and KCNK9 downregulation (Fig. 5k–n). Here, KCNK9 is linked to neoplasm.